Clinical trial
A Phase III, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Prophylaxis in Patients With Type 3 Von Willebrand Disease
NCT06998524 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Prophylaxis in Patients With Type 3 Von Willebrand Disease
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- June 27, 2025
- Completion date
- April 30, 2029
- Enrollment
- 75 (estimated)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.